Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen
© Zheng et al; licensee BioMed Central Ltd. 2007
Received: 24 October 2006
Accepted: 30 March 2007
Published: 30 March 2007
We have developed a cell-based vaccine that features the expression of both CD80 and CD86 on the surface of a murine neuroblastoma cell line. The cellular immunity induced by this vaccine is enhanced by treatment with antibody that interferes with T-regulatory cell (Treg) function and we report here that immunization combined with interfering with Treg function also produces a profound serological effect. Serum from mice immunized with our cell-based vaccine in the context of Treg blockade was used to screen a cDNA expression library constructed from the parental neuroblastoma tumor cell line, AGN2a.
Serum from mice vaccinated in the context of Treg blockade identified a number of potentially oncogenic transcripts that may serve as important immune targets in a tumor-derived cDNA library screen. This novel approach identified far more candidates than could be seen with serum derived from vaccine-treated only, Treg-depleted only, or tumor-bearing mice. The most commonly identified tumor-associated antigen, using serum from immunized and Treg-depleted mice, was the DEK oncogene. Altered expression of the DEK oncogene has been implicated in a number of human cancers. Importantly, we were able to demonstrate that the DEK oncogene also induces a T cell response.
The use of post-vaccine immune serum in this report differs from previous approaches where serum collected at the time of cancer onset or diagnosis and was used for tumor antigen identification. We hypothesize that the use of diagnostic serum samples may be inadequate for the clinical translation of this approach, and that identification of protective immunogenic tumor antigens may require the use of serum from post-treatment or vaccinated subjects. The identification of DEK as a tumor-associated antigen capable of eliciting a T cell response validates our experimental approach and argues for the antigens we have identified here to be evaluated as targets of effector immunity and as vaccine candidates.
Advanced neuroblastoma poses a grave clinical challenge and still awaits effective therapy. Early clinical observations, combined with a slight but demonstrable positive impact of bone marrow transplantation on outcome has motivated the development of immune approaches to therapy [1–4]. In murine models of human neuroblastoma, anti-tumor immunity can be generated using cell-based vaccines where tumor cells have been genetically modified to express soluble cytokines or cell-surface immunostimulatory molecules [5–7]. Our own work has demonstrated that cancer cell-based vaccines expressing multiple immune co-stimulatory molecules in the murine neuroblastoma cell line AGN2a can transform this tumor cell line in to a vaccine that induces strong cell-based immunity to the unmodified parental cell line [8, 9]. Based on the ability to induce an immune response with cancer cell-based vaccines, human trials with neuroblastoma patients have been carried out . Although these cell-based cancer vaccines did not prove immediately effective, they were demonstrated to be safe and are ripe for further optimization .
In experimental systems, immunity to neuroblastoma can be amplified by the blockade of T-regulatory cell (Treg) function with anti-CD25 antibody (B.D. Johnson, et al., 2007, J. Immunother., in press). Treg are known to suppress the immune response to self-antigens, including tumor-self antigens, and thwarting this tolerogenic role by their depletion has become a major focus in the development of new immunotherapeutic strategies to treat human malignancy [12, 13]. Golgher et al. have demonstrated that CD25+ T cell depletion uncovers immune responses to the tumor cell type used as a vaccine, and importantly that this response broadens to include other syngeneic tumor cell types . Given the ability to induce immune recognition of what are normally considered "self" antigens upon Treg blockade, we reasoned that treatment of experimental animals with cell-based cancer vaccines in the context of anti-CD25 antibody treatment would induce a strong anti-neuroblastoma immune response. The proposed use of serology to uncover T cell antigens is supported by the recent description of antibody as well as T cell responses to the DBY minor histocompatibility antigen in allogeneic stem cell transplantation [15, 16]. The breaking of tolerance to self-antigens with Treg depletion may be functionally analogous to the anti-tumor effect seen in allogeneic bone marrow transplantation, whose primary side-effect, graft-versus-host disease, is evidence that tolerance to normal self antigens has been modified.
The serological analysis of recombinant cDNA expression libraries (SEREX) constructed from patient tumor was established by Sahin and Tureci who demonstrated that this process identifies T-cell antigens as well as B-cell antigens [17, 18]. SEREX continues to be employed in patient studies and has even proven to identify intracellular antigens targeted by the immune system . The identification of the NY-ESO-1 antigen in patients by SEREX demonstrated that both MHC class II restricted epitopes and MHC class I-restricted (HLA-A2) epitopes, targets of cytotoxic T cell responses, could be identified with this technique . We present a new means to identify immunogenic tumor antigens. In this report we employ serum from experimental animals that have been vaccinated in the context of anti-CD25 antibody treatment, as opposed to using sera from tumor-bearing animals, which would be the equivalent of using serum from newly diagnosed patients. The use of immune serum-SEREX has allowed us to identify new tumor-associated antigens in our neuroblastoma model. Notably, we demonstrate that one of the antigens identified by our immune-SEREX approach, the DEK oncoprotein, induces a T cell response as well as an antibody response. Translation of this concept in to clinical studies would require the used of post-treatment or even post-vaccination serum, as opposed to the initial samples commonly harvested at the time of diagnosis.
Neuroblastoma antigens identified by immune serum and SEREX.
Identity of cDNA SEREX hit
p53 interaction, blocks apoptosis
DNA binding/chromosomal organization,
Proofreading of splicing
Fused to can in leukemia
Hspa8, heat shock protein 8 (Hsc70)
Promotes cell-cycle progression (w/cyclin D1)
Binds/regulates dbl proto-oncogene
Fusip1, FUS interacting protein (Nssr, TASR)
Neuronal Differentiation, modulates
neuronal mRNA splicing
Over-expressed in liposarcoma and leukemia
Hmgb1, high mobility group box-1
DNA binding, architecture regulation
Atp5c1, ATP synthase (mitochondrial F1 complex, gamma polypeptide 1)
ATP biosynthesis, upregulated in STI571-resistant leukemia
Sfrs5, splicing factor, arginine/serine-rich (SRp40, HRS)
Splicing factor, Akt substrate
Prpf38b, pre-mRNA processing factor (PRP38)
snRNP, required for spliceosome activity
Tuba1, tubulin, alpha 1
Upregulated in carcinoma
Chn1, chimerin 1
Csnk2a1, casein kinase II, alpha 1 polypeptide
Mkks, McKusick-Kaufman syndrome protein
Chaperonin, required for cytokenesis
Mier1, mesoderm induction early response 1 (Mi-er1, er1)
Fibroblast growth factor induced, HDAC1 interaction, transcription factor
MTTR, 5-methyltetrahydrofolate-homocysteine methyltransferase reductase
Mutations seen in neural tube defects
Influences ALL susceptibility
Psma6, proteasome subunit, alpha type 6
Upregulated in hepatocellular ca.
Cell surface tetraspannin, neuronal differentiation and neuroblastoma marker
Chromogranin B, Chgb (secretogranin I)
Present in neuroblastoma secretory vesicles
Brd2, bromodomain containing 2 (NAT, Rnf3, Ring3, Fsrg1)
Binds to KSHV, LANA-1 protein
Crlf3, cytokine receptor-like factor 3
Upregulated in skin cancer
Plod3, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (LH3)
Upregulated in chemo resistant ca.
Immt, inner membrane protein mitochondrial (HMP; P87; P89; P87/89)
Suv39h2, suppressor of variegation 3–9 homolog 2
Epigenetic regulation of telomere length
Serbp1, serpine1 mRNA binding protein
inferred function (by Gene Ontology)
Dus3l, dihydrouridine synthase 3-like
inferred function (by Gene Ontology)
Slc9a6, Solute carrier family 9 (Na+/H+ exchanger)
inferred function (by Gene Ontology)
Riken cDNA, predicted protein
The cluster analysis displayed in Figure 1, identifies four different categories of neuroblastoma antigen expression profiles. In Cluster 1, transcripts are over-expressed in the mouse neuroblastoma cell lines in a tumor-restricted manner: Chgb, Dus31, 2310042G06Rik, Psma6 (proteasome subunit), Csnk2a1 (casein kinase), Mtrr (metabolic activation), and Hspa8 (heat shock protein). An interesting sub-group within this cluster includes Chgb, chromogrannin B, which is known to be associated with sympathetic neurons and which is also found in adrenal tissue. In Cluster 2 we find transcripts that are overexpressed in neurboastoma cells lines as well as spleen or lung: CD9 (tetraspanin, neuroblastoma marker), Plod3 (collagen biosynthesis), Fusip1 (neuronal differentiation), Brd2 (transcription), Tuba2 (tubulin alpha), DEK, Prpf38b, Hmgb1 (inflammatory mediator), and Serbp1 (serpine). Some of the proteins in this group, like CD9 and Hmgb1function as immune modulators. Cluster 3 (Crlf3 and Mier 1) and Cluster 4 (Atp5c1, Suv39h1, Immt, Slca6) are not over-expressed in neuroblastoma cells lines and seem unlikely to play a role in neuroblastoma. They may either be cross-reactive antigens or specific targets of auto-immune responses. We propose that each of the Cluster 1 and Cluster 2 transcripts should be explored with regard to tumorigenesis and immunogenicity.
The second source of antigen-presenting cells used to monitor anti-DEK responses was the AGN2a cell line we produced that over-expresses DEK (Figure 2). CD8+ T cells were purified from naïve mice, mice treated only with PC61 (anti-CD25 antibody), or from mice that received both the AGN2a-CD80/86 vaccine and PC61. While naïve or PC61-treated mice did not show any IFN-γ ELISPOT activity in response to AGN2a, vaccinated mice showed relatively strong ELISPOT reactivity against both unmodified AGN2a tumor cells and heightened responses against the DEK-over-expressing cell line, Figure 6B. Taken together these assays demonstrate that anti-DEK CD8 T cell responses are induced by our vaccine+PC61 immunization protocol. This also validates that our serologic cDNA screening assay, based on the use of immune serum rather than tumor-onset serum, can identify important T cell epitopes.
SEREX analysis has been used to identify tumor-associated antigens in a number of malignancies. Primarily, patient serum has been used to screen tumor-derived cDNA libraries. The immunological rationale for the SEREX approach is that unique tumor antigens should induce an antibody response. However, the induction of tolerance to tumor antigens is now recognized to be a formidable obstacle to inducing anti-tumor immunity. It may well be that the antibody specificities present in tumor-bearing patients or animals represent antigens to which a tolerized, or non-tumoricidal immune response has been generated.
During our use of a pre-clinical model to test novel cell-based vaccines for neuroblastoma, we found that transfection of the AGN2a cell line with immune co-stimulatory molecules transforms the immunologically silent tumor into a powerful locus of immune activation. Moreover, immunization with a genetically modified tumor cell line, AGN2a-CD80/86, is even more effective when administered in the context of Treg blockade/depletion with an anti-CD25 mAb, PC61. In using PC61 it is also possible to deplete activated effectors, as all T cells express CD25 upon stimulation. Although we have not directly explored effects on antibody production, a single round of PC61 treatment prior to two weekly injections with a cell-based vaccine is superior to depletion three days prior to each of the weekly vaccinations when testing for cell-mediated anti-tumor immunity (Johnson, B.D., et al., 2007. CD25+ Regulatory T Cell Inhibition Enhances Vaccine-induced Immunity to Neuroblastoma, J. Immunother., in press). Based on this finding we used a single round of PC61 treatment in the studies presented here.
We have used serum from mice immunized twice weekly in the context of Treg-depletion to carry out a SEREX analysis, reasoning that unique neuroblastoma antigens may be uncovered in vaccinated, as opposed to tumor-bearing, animals. When an AGN2a cDNA library we prepared was screened for the ability to express IgG-reactive antigens, a number of transformation-associated proteins were identified, Table 1. These antigens were over-expressed in two other murine neuroblastoma cell lines as well, when compared to normal tissues, Figure 1, demonstrating that immunization in the context of Treg inhibition can identify unique and potentially important transcripts. What was most striking about our data was the abundant number of "hits" that were generated against the DEK oncogene. DEK was indeed over-expressed in neuroblastoma cell lines, Figure 1, and was recognized by immune serum in ELISAs, Figure 5. Our SEREX analysis also identified some antigens that were not over-expressed in neuroblastoma, yet these antigens still induced an antibody response. This response may either be due to the generation of cross-reactive antibody, or the antigens may be targets of an induced autoimmune response. It is also possible that point mutations in these antigens may have generated an immune response to them. Direct sequence analysis of these proteins will be required to confirm or refute this possibility and will be explored in future studies.
The combination of Treg depletion and vaccination may also induce CD8 effector cells. Recent descriptions of auto-reactive CD4 T cells that have expanded in vitro upon Treg depletion from healthy individuals including those specific for NY-ESO-1, tyrosinase, and GAD65 (a type 1 diabetes-associated autoantigen) support this hypothesis and suggest that Treg modulation may be essential for inducing anti-tumor immunity [20, 21].
The identification of DEK as a tumor-associated antigen in murine neuroblastoma cell lines is fascinating due to the expression of DEK in an expanding number of human cancers. Both DEK and E2F3 have been identified as over-expressed transcripts due to chromosome 6p gains in retinoblastoma, a common pediatric malignancy . Genomic gains of oncogenes like DEK are likely to be selected for because they confer a growth advantage to the malignancy, and 6p gains have been described in a number of malignancies including bladder and gastroesophageal cancer, osteosarcoma, and melanoma [23–26]. DEK was first identified as part of a fusion protein with the CAN/NUP 214 nucleoprotein in an acute myeloid leukemia, AML, sub-type through an "in-frame" translocation of chromosome 6 and 9 . Biochemically, DEK is known to regulate transcription and contains a DNA binding domain, several phosphorylation sites, and a SAF-Box (scaffold attachment factor). DNA binding is dependent on phosphorylation by casein kinase 2 (CK2) which appears to regulate its transcriptional regulatory function [28–30]. Of note, we also identified CK2 by immune serum-SEREX, Table 1. Most recently DEK was demonstrated to reside in the spliceosome, and that upon phosphorylation, DEK associates with U2AF, enforcing 3' splice site discrimination, preventing U2AF from binding to pyridine tracts not followed by AG sequence . The association with DEK over-expression or inactivation with human disease may be related to alterations in splice-site recognition and intron removal . Evidence that DEK regulates key genomic responses to DNA damage was demonstrated by the ability of a partial fragment of DEK, isolated by a cDNA library screen, to complement an ataxia-telangiectasia phenotype in vitro . In our immune-SEREX screen we identified partial transcripts as well, generated from an internal ATG sequence, that were recognized by immune sera (not shown). The association of DEK with cellular transformation has left little doubt of its oncogenic potential. DEK has been shown to inhibit senescence in cells infected with high-risk papillomavirus and to associate with the latency protein LANA-1 expressed by KSHV (Kaposi's sarcoma-associated herpesvirus) [34, 35]. In the AML subset containing the t(6;9)(p23;q34) chromosomal abnormality, monitoring of the DEK-CAN transcript by RT-PCR shows an exact correlation to therapeutic outcome .
DEK is a nuclear protein, and antibody responses to DEK have been proposed to be indicators of autoimmune disease. However, in a report by Dong et al., it was proposed that anti-DEK antibodies are not a marker for any specific disease, but a marker for a subset of autoimmunity associated with IFN-γ production . This is fascinating, as the breaking of tolerance to a self/tumor-associated antigen, as demonstrated by an IFN-γ mediated immune response, is a key characteristic of generating Th1 immunity. Further evidence for the ability to generate an immune response specific for DEK was seen when a human CD4 T cell clone specific to the DEK-CAN fusion protein produced IFN-γ upon co-culture with dendritic cells loaded with either apoptotic or necrotic t(6;9) leukemia cells . Another potential mechanism for the induction of an immune response to self-proteins is the production of a truncated transcript by the tumor itself. Immune responses to a truncated HER-2/neu protein are far greater than to native protein and have become a new focus for vaccine development . Although full-length recombinant DEK was used throughout our studies, the isolation of a partial transcript from the AGN2a cDNA library leaves this a possibility in our in vivo vaccine studies.
SEREX-based analysis of human cancers is entering a new phase of development. Studies from the laboratory of Dr. L. Old are beginning to describe how in different clinical situations, it is the SEREX-identified antibody targets that define discrete sets of over-expressed protein antigens that predict tumor pathophysiology. Notably, their current hypothesis is that SEREX specifically identifies tumor/self antigens that are recognized by CD4+CD25+ regulatory T cells, and that without induction of an inflammatory immune response that includes CTL activity, immunization with SEREX-identified antigens alone may actually enhance tumor progression [40, 41]. Our approach avoids this concern, in that tumor antigens we identify in the context of cell-based vaccination and Treg inhibition occur in a physiological environment where protective cytolytic T cell responses are being induced by the tumor cell-based vaccine . We anticipate testing our hypothesis in human subjects immediately after the initial course of chemotherapy, where tumor antigen has been newly loaded in to the antigen-presenting cells, or following specific immunotherapeutic trials.
We have presented a new rationale for tumor antigen identification using serum from mice vaccinated in the context of altered tolerance, by blocking the function of Treg cells. This procedure, which was developed for inducing strong T cell responses, also generated a strong serological response. Few if any antigens were identified in tumor-bearing, or Treg-blocked only animals. However, vaccination in the context of Treg depletion produced serum from which we were able to generate a candidate tumor antigen list, and we demonstrate that for one of these antigens, the DEK oncogene, a strong T cell response is also induced. A number of these antigens are associated with tumorigenicity and should be explored in their own right. We conclude that tolerance mechanisms are operative in tumor-bearing animals, and that these may block effective tumor antigen identification by serological screening of cDNA libraries (SEREX). To extrapolate these findings to human disease, serology-based antigen discovery should be carried out not with onset or diagnostic serum (which is most commonly banked), but with serum derived from treated patients in which antigen loading in to the immune system is optimal and in which Treg effects may be minimized.
Mice and tumor cell lines
A/J mice, 6–8 weeks of age, were purchased from Jackson Laboratories (Bar Harbor, ME). Mice were housed in the Medical College of Wisconsin Biomedical Resource Center (AALAC accredited) and all protocols were approved by the MCW Institutional Animal Care and Use Committee. AGN2a, an aggressive clone of Neuro2a, was derived from successive in vivo passage, and AGN2a transfectants that permanently express CD80 and CD86 (AGN2a-CD80/86) have been previously described .
Generation of immune serum
A/J mice were given two weekly subcutaneous (s.c.) injections of 2 × 106 irradiated AGN2a-CD80/86 cells. For blockade/depletion of T-regulatory cells, mice received 500 μg of bioreactor generated (Integra CL 1000, Chur, Switzerland) anti-CD25 monoclonal antibody (mAb), clone PC61, by intraperitoneal (i.p.) injection 3 days prior to the first vaccination. Blood was collected 5 days after the second vaccination, incubated at 37°C for 30 min, centrifuged at 800 × g for 10 min, and then stored at -80°C.
Construction of cDNA expression libraries
Total RNA was isolated from AGN2a using Trizol (Invitrogen) according to the manufacturer's protocol and mRNA purified using the Oligotex mRNA Kit (Qiagen). 5 μg of purified poly-A mRNA was used to construct a cDNA library using the ZAP Express cDNA Synthesis Kit and ZAP Express cDNA Gigapack III Gold Cloning Kit (Stratagene, Inc., La Jolla, CA). Three libraries based on size fractionation of packaged cDNA inserts were created. cDNA fragments were cloned into the λZAPII Express Vector (Stratagene), packaged into phage particles, and used to transfect E. coli, resulting in at least 1.25 × 105 primary recombinants per library. We screened the library with the highest titer (2 × 107 pfu/ml) and the most representative insert size species for mammalian mRNA (600–2500 bp as determined by PAGE).
Immunoscreening of the AGN2a cDNA library
Proteins encoded by the cDNA expression library were probed with sera from AGN2a-CD80/86+PC61 vaccinated mice (pooled from 5 mice). Recombinant phage at a concentration of 5,000 pfu per plate (150 mm2) were amplified for 4 hr at 42°C until plaques were visible and then transferred to nitrocellulose membranes pre-wetted with 10 mM IPTG (Invitrogen) for an additional 3.5 hr at 37°C. Membranes were then washed 3 times with TBST (20 mM Tris-Cl, 150 mM NaCl, 0.05% Tween 20, pH7.5), blocked with 1% bovine serum albumin (BSA, Sigma A3803) in TBS, and then incubated with a 1:250 dilution of immune serum, which had been pre-adsorbed with E. coli phage lysate following the manufacturer's protocol (Stratagene). Bound antibody was detected by incubation with alkaline phosphatase-conjugated rabbit anti-mouse IgG (H+L) (Abcam) and visualized by staining with 4-nitro blue tetrazolium chloride/5-bromo-4-chloro-3-indoyl-phosphate (NBT/BCIP, picoBLUE Immunoscreening Kit, Stratagene). Positive clones were subcloned and re-screened as above. In vivo excision was carried out with plaques that proved positive upon secondary screening in order to generate the pBK-CMV phagemid containing the cloned insert. Phagemid was isolated with QIAprep columns (QIAGEN) and the size of the cDNA insert analyzed by XhoI/EcoRI restriction digest. Inserts were sequenced using T7 and T3 primers by automated DNA sequencing (ABI 3100, MCW Protein and Nucleic Acid Facility). To verify that phagemid-encoded cDNA was expressed by AGN2a, newly generated cDNA (with Olido-dT and SuperScript III, as above) was screened by PCR (34 cycles at an annealing temperature of 55°C) using primers specific for each gene. Primers were designed on-line using Primer3 .
Expression of DEK protein
Full-length DEK (GeneBank, BC055451) was cloned from AGN2a cDNA using the following primers: (fwd) 5'-GGAATTCCATATGCCGGGTCCCAGGGAAGAG, (rev) 5'-CGGGATCCTCAAGAAATTAGCTCTTTTACAG. A small portion of non-translated 5' sequence was included to produce an in-frame product for protein expression and to overcome the repetitive GC-rich region just prior to the start codon. Primers used to amplify and clone EGFP were: (fwd) 5'-CATATGGTGAGCAAGGGCGAG, (rev) 5'-GGATCCGCTTTACTTGTACAGCT. NdeI and BamHI restricted PCR fragments were ligated into pET-15b (Novagen, Madison, WI) and recombinant plasmid insert sequence (pET-15/DEK and pET-15/EGFP) was verified by DNA sequencing. Plasmids were transformed into E. coli strain BL21 (DE3) and gene expression induced with 0.8 mM isopropyl-β-D-thiogalactopyranoside (IPTG, Invitrogen). Prokaryotically-expressed proteins were purified using a Ni-NTA Purification System (Invitrogen) and analyzed by SDS-PAGE and western blotting. Bacterial lysates were lysed in reducing loading buffer (NuPAGE system, Invitrogen), proteins resolved by SDS-PAGE, and the proteins transferred to PVDF membranes (Invitrolon, 0.45 μm, Invitrogen) using a NuPAGE Bis-Tris electrophoresis system (Invitrogen). Blots were probed with anti-human DEK (BD Biosciences) and anti-His antibody (Serotec, Raleigh, MC) at a 1:1000 dilution, followed by alkaline phosphatase conjugated rabbit anti-mouse IgG (H+L) (Abcam) at a 1:2500 dilution. NBT/BCIP was used for AP detection (picoBLUE Immunoscreening Kit, Stratagene).
To produce stable transfected cell lines, AGN2a was transfected by electroporation with the pcDNA3.1-Hygro vector (Invitrogen) encoding DEK. Transfected cells were selected by culture in 400 μg/ml hygromycin (Invitrogen), cloned by limiting dilution, and subclones selected for uniform DEK expression by immunofluorescent staining, as follows: 1 × 105 cells were plated overnight in glass chamber slides (Nalge, Nunc International), washed 2× with PBS, and fixed with 4% paraformaldehyde (Sigma) for 15 minutes at room temperature. The slides were rinsed in PBS, blocked with 10% normal goat serum, and then incubated overnight at 4°C with mouse anti-human DEK (1:100, BD Biosciences) or isotype control (IgG1, 1:100, BD Biosciences). Slides were then rinsed in PBS and then incubated for 1 hour with Alexa Fluor 555-conjugated goat anti-mouse IgG (H+L), (1:1000, Invitrogen). After rinsing in PBS, the cells were incubated for 5 minutes with 0.3 mM DAPI (Invitrogen) at room temperature. Slides were mounted with Vectashield (Vector Laboratories) and microscopically inspected.
Western blot analysis
AGN2a cells were washed twice with PBS, resuspended in PBS at 5 × 106/ml, and diluted in three volumes 4× sample buffer (NuPAGE LDS Sample Buffer, Invitrogen, Inc.). (A) Lane 1, molecular weight (mw) marker and lanes 2 through 5, boiled AGN2a cell lysate (5 × 104 cell/well). After resolution of proteins by SDS-PAGE (12%, NuPAGE gel system, Invitrogen, Inc.), proteins were transferred to PVDF membrane using a Bis-Tris electrophoresis buffer system and transferred to Invitrolon PVDF membrane (as above), then cut into strips. Lanes were blocked by incubation for 1 hr at room temperature in 5% non-fat dry milk and 1% BSA in Tris-buffered saline, pH 7.5, rinsed and then incubated in: Lane 2, serum from naïve mice; Lane 3, serum from PC61 treated mice; Lane 4, serum from AGN2a-CD80/86 immunized mice; and Lane 5, serum from AGN2a-CD80/86 immunized +PC61 treated mice, diluted 1:100 in blocking buffer. Bound antibody was detected with biotin-conjugated goat anti-mouse IgG (Biotin-SP-conjugated AffiniPure Goat Anti-Mouse IgG, Fcγ Fragment Specific, Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) diluted 1:1000 in blocking buffer, washed, then incubated with AP labeled-ExtraAvidin (Extravidin-Alkaline Phosphatase, Sigma) and detected with picoBLUE as above. Data is representative of more than three separate experiments. (B) Lane 1, molecular weight marker; Lane 2, Coomassie blue stain of proteins resolved by SDS-PAGE of the AGN2a cell lysate.
Vaccination and immune assays
A/J mice were immunized by subcutaneous (s.c.) injection of 2 × 106 irradiated (5000 rad) AGN2a-CD80/86 cells cultured in DMEM supplemented with 2% mouse serum (Equitech-Bio) or 10% FBS (Gemini Bio-Products) in the context of PC61 treatment (as above). Five days following the second of two weekly vaccinations, splenocytes were collected, depleted of red cells, and CD8+ T cells purified using the CD8a (Ly-2) Microbead kit (Miltenyi Biotech) on an AutoMACS device (Miltenyi Biotech). ELISPOT analysis to enumerate CD8+ IFN-γ-producing cells was carried out using the BD ELISPOT mouse IFN-γ Set and 96-well PVDF membrane plates (Millipore, Bedford, MA) according to the manufacturer's protocols. In some assays, peritoneal exudate cells (PEC) were used as antigen-presenting cells. 1 × 105 PEC from naïve A/J mice were placed in ELISPOT wells and loaded with protein by incubating in 100 μl media containing recombinant DEK or EGFP at 25 μg/ml for 4 hours at 37°C. 1 × 105 CD8+ T cells (in 100 μl) were added to each well for 18 hr to test for antigen recognition. For direct recognition of tumor cells, 1 × 104 neuroblastoma cells (AN2a or AGN2a/DEK) were incubated with 5 × 104 CD8+ T cells. Spots were counted using an automated reader (Immunospot 3, C.T.L., Ltd., Cleveland, OH).
DEK-specific IgG was detected by coating 96-well plates (EIA/RIA, Costar, Corning, NY) with bacterially-expressed DEK or EGFP (1 μg per well) in carbonate buffer (45.3 mM NaHCO3, 18.2 mM Na2CO3, pH 9.6). Diluted sera was added to blocked wells and detected with rabbit anti-mouse IgG (H+L) labeled with alkaline phosphatase (Abcam) and developed with NNBT/BCIP (Stratagene).
The normal mouse tissues (brain, heart, lung, rib cage, spleen, liver and kidney) and tumors established using TBJ and Neuro-2a murine neuroblastoma cell lines were used for microarray analysis. For each tissue or tumor, at least two samples were used. Total RNA was purified using a combination of Trizol extraction followed by Qiagen column purification . We utilized mouse cDNA microarray chips consisting of 19940 probes representing 13,958 non-redundant genes in a cDNA microarray experiment carried out precisely as previously described . NIH3T3 RNA was used as reference in all hybridizations. To investigate the expression of SEREX identified transcripts in different mouse tissues and neuroblastoma cell lines, we used UGRepAcc to match the SEREX identified genes and the genes existing in cDNA array, 22 of 25 SEREX-identified genes having matches. In the case of multiple clones representing the same gene, the average of expression ratio was used. The data were log2 transformed and z-score normalization was performed across samples for each gene. Hierarchical clustering analysis was performed using the Pearson distance as the distance measure.
This work was supported by the Midwest Athletes Against Childhood Cancer (MACC Fund, Inc., Milwaukee, WI).
- Evans AE, Hummeler K: The significance of primitive cells in marrow aspirates of children with neuroblastoma. Cancer. 1973, 32: 906-912. 10.1002/1097-0142(197310)32:4<906::AID-CNCR2820320423>3.0.CO;2-6.View ArticlePubMedGoogle Scholar
- Bill AH: The implications of immune reactions to neuroblastoma. Surgery. 1969, 66 (2): 415-418.PubMedGoogle Scholar
- Hellstrom I, Hellstrom KE, Pierce GE, Bill AH: Demonstration of cell-bound and humoral immunity against neuroblastoma cells. ProcNatlAcadSciUSA. 1968, 60: 1231-1238.View ArticleGoogle Scholar
- Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. New England Journal of Medicine. 1999, 341 (16): 1165-1173. 10.1056/NEJM199910143411601.View ArticlePubMedGoogle Scholar
- Katsanis E, Orchard PJ, Bausero MA, Gorden KB, McIvor RS, Blazar BR: Interleukin-2 gene transfer into murine neuroblastoma decreases tumorigenicity and enhances systemic immunity causing regression of preestablished retroperitoneal tumors. Journal of Immunotherapy. 1994, 15: 81-90. 10.1097/00002371-199402000-00001.View ArticlePubMedGoogle Scholar
- Hock RA, Reynolds BD, Tucker-McClung CL, Kwok WW: Human class II major histocompatibility complex gene transfer into murine neuroblastoma leads to loss of tumorigenicity, immunity against subsequent tumor challenge, and elimination of microscopic preestablished tumors. Journal of Immunotherapy. 1995, 17: 12-18. 10.1097/00002371-199501000-00002.View ArticlePubMedGoogle Scholar
- Katsanis E, Bausero MA, Xu H, Orchard PJ, Xu Z, McIvor RS, Brian AA, Blazar BR: Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing. Cancer Immunol Immunother. 1994, 38: 135-141.View ArticlePubMedGoogle Scholar
- Johnson BD, Yan X, Schauer DW, Orentas RJ: Dual expression of CD80 and CD86 produces a tumor vaccine superior to single expression of either molecule. Cellular Immunology. 2003, 222: 15-26. 10.1016/S0008-8749(03)00079-0.View ArticlePubMedGoogle Scholar
- Johnson BD, Gershan JA, Natalia N, Zujewski H, Weber JJ, Yan X, Orentas RJ: Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice. Journal of Immunotherapy. 2005, 28: 449-460. 10.1097/01.cji.0000171313.93299.74.View ArticlePubMedGoogle Scholar
- Rousseau RF, Haight AE, Hirschmann-Jax C, Yvon ES, Rill DR, Mei Z, Smith SC, Inman S, Cooper K, Alcoser P, Grilley B, Gee A, Popek E, Davidoff A, Bowman LC, Brenner MK, Strother D: Local and systemic effects of an allogeneic tumor cell vaccine combining human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood. 2003, 101 (5): 1718-1726. 10.1182/blood-2002-08-2493.View ArticlePubMedGoogle Scholar
- Rousseau RF, Brenner MK: Vaccine therapies for pediatric malignacies. The Cancer Journal. 2005, 11 (4): 331-339.View ArticlePubMedGoogle Scholar
- Dudley ME, Wunderlich J, Robbins PF, Yang JC, Hwu P, Schwartsentruber DJ, Topalian S, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002, 298: 850-854. 10.1126/science.1076514.PubMed CentralView ArticlePubMedGoogle Scholar
- Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Huniyasu Y, Nomura T, Toda M, Takahashi T: Immunologic tolerance maintained by CD25+CD4+ regualtory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunological Reviews. 2001, 182: 18-23. 10.1034/j.1600-065X.2001.1820102.x.View ArticlePubMedGoogle Scholar
- Golgher D, Jones E, Powrie F, Elliot T, Gallimore A: Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. EurJImmunol. 2002, 32: 3267-3275.Google Scholar
- Miklos DB, Kim HT, Zorn E, Hochberg EP, Guo L, Mattes-Ritz A, Viatte S, Soiffer RJ, Antin JH, Ritz J: Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood. 2004, 103: 353-359. 10.1182/blood-2003-03-0984.PubMed CentralView ArticlePubMedGoogle Scholar
- Zorn E, Miklos DB, Floyd BH, Mattes-Ritz A, Gua L, Soiffer RJ, Antin JH, Ritz J: Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. JExpMed. 2004, 199 (8): 1133-1142.View ArticleGoogle Scholar
- Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundshuh M: Human neoplasms elicit multiple specific immune responses in the autologous host. ProcNatlAcadSciUSA. 1995, 92: 11810-11813.View ArticleGoogle Scholar
- Sahin U, Tureci O, Pfreundshuh M: Serological identification of human tumor antigens. Current Opinion in Immunology. 1997, 9: 709-716. 10.1016/S0952-7915(97)80053-2.View ArticlePubMedGoogle Scholar
- Chen YT, Scanlan MJ, Obata Y, Old LJ, Rosenberg SA: Identification of Human Tumor Antigens by Serological Expression Cloning. Prinicples and Practice of Biological Therapy of Cnacer. 2000, Philadelphia , Lippincott Williams & Williams, Third: 557-Google Scholar
- Nishikawa H, Jäger.E., Ritter G, Old LJ, Gnjatic S: CD4+ CD25+ regulatoy T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood. 2005, 106: 1008-1011. 10.1182/blood-2005-02-0607.View ArticlePubMedGoogle Scholar
- Danke NA, Koelle DM, Yee C, Beharay S, Kwok WW: Autoreactive T cells in healthy individuals. Journal of Immunology. 2004, 172: 5967-5972.View ArticleGoogle Scholar
- Grasemann K, Gratias S, Stephan H, Schuler A, Schramm A, Klein-Hitpass L, Rieder H, Schneider S, Kappes F: Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. Oncogene. 2005, 24: 6441-6449.PubMedGoogle Scholar
- Hoglund M, Gisselsson D, Hansen GB, White VA, Sall T, Mitelman F, Horsman D: Dissectingg karyotypic paterns in malignant melanomas: temporal clustering of losses and gains in melanoma karyotypic evolution. International Journal of Cancer. 2004, 108: 57-65. 10.1002/ijc.11558.View ArticleGoogle Scholar
- Koon N, Zaika A, Moskaluk CA, Frierson HF, Knuutila S, Powell SA, El-Rifai W: Clustering of molecular alterations in gastroesophageal carcinomas. Neoplasia. 2004, 6 (2): 143-149. 10.1593/neo.03385.PubMed CentralView ArticlePubMedGoogle Scholar
- Lau CC, Harris CP, Lu XY, Perlaky L, Gogineli S, Murali C, Hicks J, Johnson ME, Davino NA, Huvos AG, Meyers PA, Healy JH, Gorlick R, Rao PH: Frequent amplification and rearrangement of chromosomal bands 6p12-021 and 17p11.12 in osteosarcoma. Genes, Chromosomes and Cancer. 2003, 39 (1): 11-21. 10.1002/gcc.10291.View ArticleGoogle Scholar
- Wu Q, Hoffmann MJ, Hartmann FH, Schulz WA: Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer. Molecular Cancer. 2005, 4 (1): 16-10.1186/1476-4598-4-16.PubMed CentralView ArticlePubMedGoogle Scholar
- von Lindern M, Fornerod M, van Baal S, Jaegle M, de Witt T, Buijis A, Grosveld G: The translocation (6;9) assocaited with a specific subtype of acute myeloid leukemia, results in the fusion of two genes DEK and CAN, and the expression of a chimeric, leukemia-specific dek-can mRNA. Molecular and Cellular Biology. 1992, 12 (4): 1687-1697.PubMed CentralView ArticlePubMedGoogle Scholar
- Fu GK, Grosveld G, Markovitz DM: DEK, an autoantigen involoved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer. ProcNatlAcadSciUSA. 1997, 94: 1811-1815.View ArticleGoogle Scholar
- Kappes F, Damoc C, Knippers R, Przbylski M, Pinna LA, Gruss C: Phosphorylation by protein kinase CK2 changes the DNA binding properties of the human chromatin protein DEK. Molecular and Cellular Biology. 2004, 24 (13): 6011-6020. 10.1128/MCB.24.13.6011-6020.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Kappes F, Scholten I, Richter N, Gruss N, Waldmann T: Functional domains of the ubiquitous chromatin protein DEK. Molecular and Cellular Biology. 2004, 24 (13): 6000-6010. 10.1128/MCB.24.13.6000-6010.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Soares LMM, Zanier K, Mackereth C, Sattler M, Valcarcel J: Intron removal requires proofreading of U2AF/3' splice site recognition by DEK. Science. 2006, 312: 1961-1965. 10.1126/science.1128659.View ArticlePubMedGoogle Scholar
- Waldmann T, Scholten I, Kappes F, Hu HG, Knippers R: The DEK protein-an abundant and ubiquitoous constituent of mammalian chromatin. Gene. 2004, 343: 1-9. 10.1016/j.gene.2004.08.029.View ArticlePubMedGoogle Scholar
- Meyn MS, Lu-Kuo JM, Herxzing LBK: Expression cloning of multiple human cDNAs that complement the phenotypic defects of ataxia-telangiectasia group D fibroblasts. Am J Hum Genet. 1993, 53: 1206-1216.PubMed CentralPubMedGoogle Scholar
- Krithivas A, Fujimuro M, Weidner M, Young DB, Hayward SD: Protein interactions targeting the latency-associaited nuclear antigen of Kaposi's sarcoma-associated herpesvirus to cell chromosomes. Jounral of Virology. 2002, 76 (22): 11596-11604. 10.1128/JVI.76.22.11596-11604.2002.View ArticleGoogle Scholar
- Wise-Drapper TM, Allen HV, Thobe MN, Jones EE, Habash KB, Munger K, Wells SI: The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. Journal of Virology. 2005, 79 (22): 14309-14317. 10.1128/JVI.79.22.14309-14317.2005.View ArticleGoogle Scholar
- Garcon L, Libura M, Delabesse E, Valensi F, Asnafi V, Berger C, Schmitt C, Leblanc T, Buzyn A, Macintyre E: DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification. Leukemia. 2005, 19: 1338-1344. 10.1038/sj.leu.2403835.View ArticlePubMedGoogle Scholar
- Dong X, Wang J, Kabir FN, Shaw M, Reed AM, Stein L, Andrade LEC, Trevisani VFM, Miller ML, Fuji T, Akizuki M, Pachman LM, Satoh M, Reeves WH: Autoantibodies to DEK oncoprotein in human inflammatory disease. Arthritis and Rheumatism. 2000, 43 (1): 85-93. 10.1002/1529-0131(200001)43:1<85::AID-ANR11>3.0.CO;2-D.View ArticlePubMedGoogle Scholar
- Makita M, Azuma T, Hamaguchi H, Niiya H, Kojima K, Fujuta S, Tanimoto M, Harada M, Yasukawa M: Leukemia-associated fusion proteins, dek-can and bcr-abl, represetn immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes. Leukemia. 2002, 16: 2400-2407. 10.1038/sj.leu.2402742.View ArticlePubMedGoogle Scholar
- Kitano S, Kageyama S, Nagata Y, Miyahara Y, Hiasa A, Naota H, Okumura S, Imai H, Shiraishi T, Masuya M, Nishikawa M, Sunamoto J, Akiyoshi K, Kanematsu T, Scott AM, Murphy R, Hoffman EW, Old LJ, Shiku H: HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexes with nanogels of cholesteryl pullulan. Clin Cancer Res. 2006, 12 (24): 7937-7405. 10.1158/1078-0432.CCR-06-1546.View ArticleGoogle Scholar
- Nishikawa H, Kato T, Tawara I, Takemitsu T, Saito K, Wang L, Ikarashi Y, Wakasugi H, Nakayama T, Taniguchi M, Kuribayashi K, Old LJ, Shiku H: Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. ProcNatlAcadSciUSA. 2005, 102 (26): 9253-9257.View ArticleGoogle Scholar
- Nishikawa H, Kato T, Hiasa A, Tawara I, Ikeda H, Ikarashi Y, Wakasugi H, Kronenberg M, Nakayama T, Tanigichi M, Kuribayashi K, Old LJ, Shiku H: CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. ProcNatlAcadSciUSA. 2003, 100 (19): 10902-10906.View ArticleGoogle Scholar
- Rozen S, Skaletsky H: Primer3 on the WWW for general users and for biologist programmers. Bioinformatics Methods and Protocols:Methods in Molecular Biology. Edited by: Krawetz S, Misener S. 2000, Totowa, NJ , Humana Press, 365-386.Google Scholar
- Wei JS, Greer BT, Westerman F, Steinberg SM, Son CG, Chen QR, Whiteford CC, Bilke S, Krasnoselsky AL, Cenacchi N, Catchpoole D, Berthold F, Schwab M, Khan J: Prediction of Cinical Outcome Using Gene Expression Profiling and Artifical Neural Networks for Patients with Neuroblastoma. Cancer Research. 2004, 64: 6883-3891. 10.1158/0008-5472.CAN-04-0695.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.